Who is sponsoring NCT00556088?

NCT00556088 is sponsored by SCRI Development Innovations, LLC.

What condition does NCT00556088 study?

NCT00556088 studies Solid Tumors.

What drugs are being tested in NCT00556088?

Interventions: LBH589, Paclitaxel, Carboplatin, Bevacizumab.

What is the status of NCT00556088?

NCT00556088 is currently COMPLETED.

Last reviewed 2010-12-29 · How we verify

A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors

NCT00556088 Phase 1 COMPLETED

This phase I protocol will evaluate the safety and tolerability of the combination of LBH589 and paclitaxel/carboplatin. The combination of LBH589, paclitaxel/carboplatin, and bevacizumab will also be evaluated for tolerability and preliminary antitumor activity in a subset of patients with advanced non-small cell lung cancer.

Details

Lead sponsor	SCRI Development Innovations, LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	40
Start date	2007-12
Completion	2010-07

Conditions

Solid Tumors

Interventions

LBH589, Paclitaxel, Carboplatin, Bevacizumab

Primary outcomes

Determine the maximally tolerated doses and dose limiting toxicities of LBH589 in combination with paclitaxel and carboplatin. Preliminary anti-tumor activity will also be assessed. — 18 months

Countries

United States